Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16123011rdf:typepubmed:Citationlld:pubmed
pubmed-article:16123011lifeskim:mentionsumls-concept:C1516213lld:lifeskim
pubmed-article:16123011lifeskim:mentionsumls-concept:C0026549lld:lifeskim
pubmed-article:16123011lifeskim:mentionsumls-concept:C0030193lld:lifeskim
pubmed-article:16123011lifeskim:mentionsumls-concept:C1556084lld:lifeskim
pubmed-article:16123011lifeskim:mentionsumls-concept:C0683278lld:lifeskim
pubmed-article:16123011lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:16123011lifeskim:mentionsumls-concept:C0205082lld:lifeskim
pubmed-article:16123011lifeskim:mentionsumls-concept:C0033080lld:lifeskim
pubmed-article:16123011lifeskim:mentionsumls-concept:C0038951lld:lifeskim
pubmed-article:16123011lifeskim:mentionsumls-concept:C0205088lld:lifeskim
pubmed-article:16123011pubmed:issue7lld:pubmed
pubmed-article:16123011pubmed:dateCreated2005-8-26lld:pubmed
pubmed-article:16123011pubmed:abstractTextThis study aimed to determine factors associated with the prescription of morphine to terminal cancer patients suffering from severe pain. A phone survey was conducted among a sample of French GPs, neurologists and oncologists. Two short clinical cases described a terminally-ill patient with either a peritoneal carcinosis and intestinal occlusion, or a lung cancer, and in both cases suffering from severe pain. Overall, 917 agreed to participate among the 1,743 physicians contacted (global response rate 53%). About half of respondents did not support the prescription of morphine if the patient had an intestinal occlusion. Beliefs toward morphine, uneasiness with terminally-ill patients, age and female gender were independently associated with reluctance to prescribe morphine in presented cases. Specialised training has not completely remove reluctance toward morphine prescription in end-of-life care. Non-medical factors correlated to such reluctance, and especially gender, deserve more attention.lld:pubmed
pubmed-article:16123011pubmed:languagefrelld:pubmed
pubmed-article:16123011pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16123011pubmed:citationSubsetIMlld:pubmed
pubmed-article:16123011pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16123011pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16123011pubmed:statusMEDLINElld:pubmed
pubmed-article:16123011pubmed:monthJullld:pubmed
pubmed-article:16123011pubmed:issn1769-6917lld:pubmed
pubmed-article:16123011pubmed:authorpubmed-author:GalinierAnneAlld:pubmed
pubmed-article:16123011pubmed:authorpubmed-author:Peretti-Watel...lld:pubmed
pubmed-article:16123011pubmed:authorpubmed-author:FavreRogerRlld:pubmed
pubmed-article:16123011pubmed:authorpubmed-author:ObadiaYolande...lld:pubmed
pubmed-article:16123011pubmed:authorpubmed-author:Ben...lld:pubmed
pubmed-article:16123011pubmed:authorpubmed-author:Comité de...lld:pubmed
pubmed-article:16123011pubmed:issnTypeElectroniclld:pubmed
pubmed-article:16123011pubmed:volume92lld:pubmed
pubmed-article:16123011pubmed:ownerNLMlld:pubmed
pubmed-article:16123011pubmed:authorsCompleteYlld:pubmed
pubmed-article:16123011pubmed:pagination733-40lld:pubmed
pubmed-article:16123011pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:meshHeadingpubmed-meshheading:16123011...lld:pubmed
pubmed-article:16123011pubmed:year2005lld:pubmed
pubmed-article:16123011pubmed:articleTitle[Morphine prescription to terminal cancer patients suffering from severe pain: results of a French survey].lld:pubmed
pubmed-article:16123011pubmed:affiliationObservatoire régional de la santé Provence Alpes Côte d'Azur, 23 rue Stanislas-Torrents, 13006 Marseille.lld:pubmed
pubmed-article:16123011pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16123011pubmed:publicationTypeEnglish Abstractlld:pubmed